Tokyo Tape
Sign in
← H.U. Group Holdings

Quarterly report · Q2

4544.TEDINET S100PJXC
Period2022-04-01 → 2022-09-30
Filed2022-11-11
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 49
MetricValuePeriodScopeSource row
Revenue¥134.1bn2022-04-01 → 2022-09-30Cons.Net sales
Revenue¥272.9bn2021-04-01 → 2022-03-31Cons.Net sales (5-year summary)
Revenue¥133.7bn2021-04-01 → 2021-09-30Cons.Net sales
Operating income¥17.7bn2022-04-01 → 2022-09-30Cons.Operating income
Operating income¥27.0bn2021-04-01 → 2021-09-30Cons.Operating income
Ordinary income¥17.8bn2022-04-01 → 2022-09-30Cons.Ordinary income
Ordinary income¥47.4bn2021-04-01 → 2022-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥26.7bn2021-04-01 → 2021-09-30Cons.Ordinary income
Profit before tax¥20.7bn2022-04-01 → 2022-09-30Cons.Income before income taxes
Profit before tax¥25.1bn2021-04-01 → 2021-09-30Cons.Income before income taxes
Net income (owners)¥15.6bn2022-04-01 → 2022-09-30Cons.Profit loss attributable to owners of parent
Net income (owners)¥29.6bn2021-04-01 → 2022-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥19.5bn2021-04-01 → 2021-09-30Cons.Profit loss attributable to owners of parent
Net income¥15.6bn2022-04-01 → 2022-09-30Cons.Profit loss
Net income¥19.5bn2021-04-01 → 2021-09-30Cons.Profit loss
Total assets¥285.9bnat 2022-09-30Cons.Assets
Total assets¥286.6bnat 2022-03-31Cons.Assets
Total assets¥271.5bnat 2021-09-30Cons.Total assets (5-year summary)
Total liabilities¥128.6bnat 2022-09-30Cons.Liabilities
Total liabilities¥146.4bnat 2022-03-31Cons.Liabilities
Net assets / equity¥157.3bnat 2022-09-30Cons.Net assets
Net assets / equity¥140.2bnat 2022-03-31Cons.Net assets
Net assets / equity¥130.9bnat 2021-09-30Cons.Net assets (5-year summary)
Cash and deposits¥37.3bnat 2022-09-30Cons.Cash and deposits
Cash and deposits¥46.5bnat 2022-03-31Cons.Cash and deposits
Cash & equivalents¥37.3bnat 2022-09-30Cons.Cash and cash equivalents
Cash & equivalents¥46.5bnat 2022-03-31Cons.Cash and cash equivalents
Cash & equivalents¥41.8bnat 2021-09-30Cons.Cash and cash equivalents
Cash & equivalents¥43.0bnat 2021-03-31dCons.Cash and cash equivalents
Operating cash flow¥15.8bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in operating activities
Operating cash flow¥55.2bn2021-04-01 → 2022-03-31Cons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow¥20.9bn2021-04-01 → 2021-09-30Cons.Net cash provided by used in operating activities
Investing cash flow−¥18.7bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in investment activities
Investing cash flow−¥30.9bn2021-04-01 → 2022-03-31Cons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥12.8bn2021-04-01 → 2021-09-30Cons.Net cash provided by used in investment activities
Financing cash flow−¥7.4bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in financing activities
Financing cash flow−¥21.7bn2021-04-01 → 2022-03-31Cons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow−¥9.3bn2021-04-01 → 2021-09-30Cons.Net cash provided by used in financing activities
EPS (basic)¥273.422022-04-01 → 2022-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥175.172022-07-01 → 2022-09-30dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥519.552021-04-01 → 2022-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥342.232021-04-01 → 2021-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥195.932021-07-01 → 2021-09-30dCons.Basic earnings loss per share (5-year summary)
EPS (diluted)¥273.382022-04-01 → 2022-09-30Cons.Diluted earnings per share (5-year summary)
EPS (diluted)¥519.422021-04-01 → 2022-03-31Cons.Diluted earnings per share (5-year summary)
EPS (diluted)¥342.12021-04-01 → 2021-09-30Cons.Diluted earnings per share (5-year summary)
Equity ratio55.0%at 2022-09-30Cons.Equity to asset ratio (5-year summary)
Equity ratio48.9%at 2022-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio48.2%at 2021-09-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 38
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-09-30−¥5.1bn
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2022-09-30−¥5.1bn
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-09-30−¥1.5bn
jpcrp040300-q2r_E00967-000Clinical Lab Testing Businessreportable segmentrevenue2022-04-01 → 2022-09-30¥85.1bn
jpcrp040300-q2r_E00967-000Clinical Lab Testing Businessreportable segmentrevenue external2022-04-01 → 2022-09-30¥85.0bn
jpcrp040300-q2r_E00967-000Clinical Lab Testing Businessreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥83m
jpcrp040300-q2r_E00967-000Clinical Lab Testing Businessreportable segmentsegment profit2022-04-01 → 2022-09-30¥2.9bn
jpcrp040300-q2r_E00967-000In Vitro Diagnostics Businessreportable segmentrevenue2022-04-01 → 2022-09-30¥40.2bn
jpcrp040300-q2r_E00967-000In Vitro Diagnostics Businessreportable segmentrevenue external2022-04-01 → 2022-09-30¥35.2bn
jpcrp040300-q2r_E00967-000In Vitro Diagnostics Businessreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥5.0bn
jpcrp040300-q2r_E00967-000In Vitro Diagnostics Businessreportable segmentsegment profit2022-04-01 → 2022-09-30¥15.7bn
jpcrp040300-q2r_E00967-000Sterilization And Related Servicesreportable segmentrevenue2022-04-01 → 2022-09-30¥13.8bn
jpcrp040300-q2r_E00967-000Sterilization And Related Servicesreportable segmentrevenue external2022-04-01 → 2022-09-30¥13.8bn
jpcrp040300-q2r_E00967-000Sterilization And Related Servicesreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥10m
jpcrp040300-q2r_E00967-000Sterilization And Related Servicesreportable segmentsegment profit2022-04-01 → 2022-09-30¥604m
—segment totalrevenue2022-04-01 → 2022-09-30¥139.2bn
—segment totalrevenue external2022-04-01 → 2022-09-30¥134.1bn
—segment totalrevenue intersegment2022-04-01 → 2022-09-30¥5.1bn
—segment totalsegment profit2022-04-01 → 2022-09-30¥19.2bn
Reconciling Itemsreconcilingrevenue2021-04-01 → 2021-09-30−¥4.9bn
Reconciling Itemsreconcilingrevenue intersegment2021-04-01 → 2021-09-30−¥4.9bn
Reconciling Itemsreconcilingsegment profit2021-04-01 → 2021-09-30−¥746m
jpcrp040300-q2r_E00967-000Clinical Lab Testing Businessreportable segmentrevenue2021-04-01 → 2021-09-30¥88.8bn
jpcrp040300-q2r_E00967-000Clinical Lab Testing Businessreportable segmentrevenue external2021-04-01 → 2021-09-30¥88.8bn
jpcrp040300-q2r_E00967-000Clinical Lab Testing Businessreportable segmentrevenue intersegment2021-04-01 → 2021-09-30¥33m
jpcrp040300-q2r_E00967-000Clinical Lab Testing Businessreportable segmentsegment profit2021-04-01 → 2021-09-30¥14.7bn
jpcrp040300-q2r_E00967-000In Vitro Diagnostics Businessreportable segmentrevenue2021-04-01 → 2021-09-30¥35.0bn
jpcrp040300-q2r_E00967-000In Vitro Diagnostics Businessreportable segmentrevenue external2021-04-01 → 2021-09-30¥30.2bn
jpcrp040300-q2r_E00967-000In Vitro Diagnostics Businessreportable segmentrevenue intersegment2021-04-01 → 2021-09-30¥4.8bn
jpcrp040300-q2r_E00967-000In Vitro Diagnostics Businessreportable segmentsegment profit2021-04-01 → 2021-09-30¥12.0bn
jpcrp040300-q2r_E00967-000Sterilization And Related Servicesreportable segmentrevenue2021-04-01 → 2021-09-30¥14.7bn
jpcrp040300-q2r_E00967-000Sterilization And Related Servicesreportable segmentrevenue external2021-04-01 → 2021-09-30¥14.7bn
jpcrp040300-q2r_E00967-000Sterilization And Related Servicesreportable segmentrevenue intersegment2021-04-01 → 2021-09-30¥10m
jpcrp040300-q2r_E00967-000Sterilization And Related Servicesreportable segmentsegment profit2021-04-01 → 2021-09-30¥1.0bn
—segment totalrevenue2021-04-01 → 2021-09-30¥138.6bn
—segment totalrevenue external2021-04-01 → 2021-09-30¥133.7bn
—segment totalrevenue intersegment2021-04-01 → 2021-09-30¥4.9bn
—segment totalsegment profit2021-04-01 → 2021-09-30¥27.7bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 532
ItemContextValueUnit
Net salesPrior1YTDDuration133739000000JPY
Net salesCurrentYTDDuration134081000000JPY
Cost of salesPrior1YTDDuration78832000000JPY
Cost of salesCurrentYTDDuration83845000000JPY
Gross profitPrior1YTDDuration54907000000JPY
Gross profitCurrentYTDDuration50236000000JPY
Selling general and administrative expensesPrior1YTDDuration27955000000JPY
Selling general and administrative expensesCurrentYTDDuration32551000000JPY
Operating incomePrior1YTDDuration26951000000JPY
Operating incomeCurrentYTDDuration17684000000JPY
Interest income noiPrior1YTDDuration18000000JPY
Interest income noiCurrentYTDDuration65000000JPY
Dividends income noiPrior1YTDDuration21000000JPY
Dividends income noiCurrentYTDDuration28000000JPY
Foreign exchange gains noiPrior1YTDDuration－JPY
Foreign exchange gains noiCurrentYTDDuration1028000000JPY
Other noiPrior1YTDDuration1280000000JPY
Other noiCurrentYTDDuration429000000JPY
Non operating incomePrior1YTDDuration1320000000JPY
Non operating incomeCurrentYTDDuration1553000000JPY
Interest expenses noePrior1YTDDuration197000000JPY
Interest expenses noeCurrentYTDDuration187000000JPY
Equity in losses of affiliates noePrior1YTDDuration1052000000JPY
Equity in losses of affiliates noeCurrentYTDDuration1153000000JPY
Other noePrior1YTDDuration277000000JPY
Other noeCurrentYTDDuration100000000JPY
Non operating expensesPrior1YTDDuration1527000000JPY
Non operating expensesCurrentYTDDuration1441000000JPY
Ordinary incomePrior1YTDDuration26745000000JPY
Ordinary incomeCurrentYTDDuration17795000000JPY
Gain on sales of noncurrent assets eiPrior1YTDDuration79000000JPY
Gain on sales of noncurrent assets eiCurrentYTDDuration2615000000JPY
Gain on step acquisitions eiPrior1YTDDuration－JPY
Gain on step acquisitions eiCurrentYTDDuration758000000JPY
Gain on reversal of subscription rights to shares eiPrior1YTDDuration40000000JPY
Gain on reversal of subscription rights to shares eiCurrentYTDDuration－JPY
Other eiPrior1YTDDuration48000000JPY
Other eiCurrentYTDDuration26000000JPY
Extraordinary incomePrior1YTDDuration168000000JPY
Extraordinary incomeCurrentYTDDuration3400000000JPY
Loss on retirement of noncurrent assets elPrior1YTDDuration35000000JPY
Loss on retirement of noncurrent assets elCurrentYTDDuration25000000JPY
Loss on valuation of investments in capital elPrior1YTDDuration149000000JPY
Loss on valuation of investments in capital elCurrentYTDDuration149000000JPY
Loss on valuation of other investments elPrior1YTDDuration619000000JPY
Loss on valuation of other investments elCurrentYTDDuration197000000JPY
Other elPrior1YTDDuration1018000000JPY
Other elCurrentYTDDuration120000000JPY
Extraordinary lossPrior1YTDDuration1823000000JPY
Extraordinary lossCurrentYTDDuration494000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 14 of 14 passed
balance sheet identityconsolidated 2022-03-31pass rounding
balance sheet identityconsolidated 2022-09-30pass
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2022-03-31pass
statement vs summary · net assetsconsolidated 2022-09-30pass
statement vs summary · net income attributable to parentconsolidated 2021-04-01/2021-09-30pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-09-30pass
statement vs summary · operating cash flowconsolidated 2021-04-01/2021-09-30pass
statement vs summary · operating cash flowconsolidated 2022-04-01/2022-09-30pass
statement vs summary · revenueconsolidated 2021-04-01/2021-09-30pass
statement vs summary · revenueconsolidated 2022-04-01/2022-09-30pass
statement vs summary · total assetsconsolidated 2022-03-31pass
statement vs summary · total assetsconsolidated 2022-09-30pass